On December 29, Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) announced that it had recently received the notice of approval of drug clinical trial approved and issued by the State Food and drug administration. The clinical trial of zg19018 tablets in the treatment of advanced malignant solid tumors with KRAS G12C mutation was approved.
According to the announcement, zg19018 is a selective covalent inhibitor of KRAS G12C independently developed by the company. It belongs to class 1 small molecule antitumor drugs and has global intellectual property rights. At present, only one drug with similar mechanism has been approved to market all over the world.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) said that the preclinical results showed that zg19018 had a significant pharmacodynamic effect of inhibiting the growth and cell proliferation of KRAS G12C mutant tumor, had long drug half-life and high oral bioavailability, and had high drug concentration in tumor and brain tissue. Zg19018 is expected to become an innovative drug for the treatment of KRAS G12C mutant tumors.
(Shanghai Securities News · China Securities Network)
